BR112013028755A2 - combinações de solifenacina e estimulantes salivares para o tratamento de bexiga hiperativa - Google Patents

combinações de solifenacina e estimulantes salivares para o tratamento de bexiga hiperativa

Info

Publication number
BR112013028755A2
BR112013028755A2 BR112013028755A BR112013028755A BR112013028755A2 BR 112013028755 A2 BR112013028755 A2 BR 112013028755A2 BR 112013028755 A BR112013028755 A BR 112013028755A BR 112013028755 A BR112013028755 A BR 112013028755A BR 112013028755 A2 BR112013028755 A2 BR 112013028755A2
Authority
BR
Brazil
Prior art keywords
sheet
solifenacin
combinations
treatment
calender
Prior art date
Application number
BR112013028755A
Other languages
English (en)
Inventor
L Duchin Kenneth
Paborji Mehdi
S Flugel Roger
Jade Limayo Hernandez Wendy
Original Assignee
Theravida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravida Inc filed Critical Theravida Inc
Publication of BR112013028755A2 publication Critical patent/BR112013028755A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

combinações de solifenacina e estimulantes salivares para o tratamento de bexiga hiperativa o processo de acordo com a invenção combina laminação e estiramento de uma chapa (101) para uma fita em uma calandra. a chapa é laminada para uma chapa laminada no interstício entre dois rolos (111,112) de calandra e a chapa laminada é estirada imediatamente em seguida para uma fita sobre a superfície de um (111) dos dois rolos de calandra. a velocidade (v3) da chapa laminada sobre a superfície do rolo de calandra (111) é mais alta do que a velocidade (111) do rolo de calandra. a posição do início do estreitamento da chapa laminada e a taxa de estreitamento podem ser facilmente controladas pelo processo proposto.
BR112013028755A 2011-05-10 2012-05-09 combinações de solifenacina e estimulantes salivares para o tratamento de bexiga hiperativa BR112013028755A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161484658P 2011-05-10 2011-05-10
PCT/US2012/037006 WO2012154774A1 (en) 2011-05-10 2012-05-09 Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder

Publications (1)

Publication Number Publication Date
BR112013028755A2 true BR112013028755A2 (pt) 2017-01-31

Family

ID=46124758

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013028755A BR112013028755A2 (pt) 2011-05-10 2012-05-09 combinações de solifenacina e estimulantes salivares para o tratamento de bexiga hiperativa

Country Status (14)

Country Link
US (3) US8940763B2 (pt)
EP (2) EP3167885A1 (pt)
JP (2) JP6068447B2 (pt)
KR (1) KR20140044816A (pt)
CN (1) CN103813792B (pt)
AU (1) AU2012253667B2 (pt)
BR (1) BR112013028755A2 (pt)
CA (1) CA2835277A1 (pt)
IL (2) IL229280B (pt)
MX (1) MX348723B (pt)
RU (1) RU2671575C2 (pt)
SG (1) SG194809A1 (pt)
WO (1) WO2012154774A1 (pt)
ZA (1) ZA201309334B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
AU2012253667B2 (en) * 2011-05-10 2017-06-01 Theravida, Inc. Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
EP3405191A4 (en) 2016-01-20 2019-09-04 TheraVida, Inc. METHOD AND COMPOSITIONS FOR TREATING HYPERHIDROSIS
US11554106B2 (en) 2017-03-07 2023-01-17 Marc Childs Prevention of the risks associated with drug-induced QT interval prolongation by using a specific inhibitor of the production of ROS of miochondrial origin

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE450087B (sv) 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
EP0310322A3 (en) * 1987-09-30 1990-10-10 Allergan, Inc Use of thromboxane b2 to constrict the pupil and lower intraocular pressure
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
NO2005012I1 (no) 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
CA2314896C (en) 1997-12-22 2005-09-13 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
PT1685839E (pt) 1997-12-22 2013-07-08 Euro Celtique Sa Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
US6482837B1 (en) 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
EP1228125A4 (en) 1999-09-14 2009-09-02 Smithkline Beecham Corp METHOD FOR PRODUCING AQUEOUS COATED BEADS
MXPA02004574A (es) 1999-11-11 2004-09-10 Pharmacia Ab Formulacion farmaceutica que contiene tolterodina y su uso.
AU2710301A (en) 2000-01-28 2001-08-07 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
EP1635795A1 (en) 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
ATE493981T1 (de) 2003-11-04 2011-01-15 Supernus Pharmaceuticals Inc Einmal tägliche dosierformen von trospium
CA2561167C (en) * 2004-03-25 2012-09-11 Astellas Pharma Inc. Composition of solifenacin or salt thereof for use in solid formulation
EP1787640A4 (en) * 2004-04-30 2012-04-11 Astellas Pharma Inc GRAINED PHARMACEUTICAL COMPOSITION WITH TEMPORARY DELIVERY FOR ORAL ADMINISTRATION AND FAST-DECREASING INTRAORAL TABLET WITH THE COMPOSITION
EP1755557A4 (en) 2004-05-19 2007-08-29 Glatt Air Tech Inc GRANULES CONTAINING MICROGRANULES AND PROCESS FOR THE PREPARATION THEREOF
WO2005123042A1 (en) 2004-06-10 2005-12-29 Glatt Air Techniques, Inc. Controlled release pharmaceutical formulation
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2006132196A1 (ja) 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation β３作動薬を含有する新規な医薬
PT1933833E (pt) 2005-09-02 2011-07-08 Theravida Inc Terapia para o tratamento da bexiga superactiva
WO2007029087A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Controlled release multiple unit formulations
US20070077300A1 (en) 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
WO2007046102A2 (en) 2005-10-19 2007-04-26 Menni Menashe Zinger Methods for the treatment of hyperhidrosis
BRPI0809563A2 (pt) 2007-03-29 2014-09-16 Panacea Biotec Ltd Formas de dosagem modificadas de tacrolimus
US7563508B2 (en) 2007-05-30 2009-07-21 Chung Shan Institute Of Science And Technology, Armaments Bureau, M.N.D. Diffusion beads with core-shell structure
WO2009003724A1 (en) 2007-07-03 2009-01-08 Synthon B.V. Tolterodine bead
EP2175843B1 (en) 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
CA2697437A1 (en) 2007-09-28 2009-04-09 Novartis Ag Pharmaceutical combination of aliskiren and valsartan
WO2009057138A2 (en) 2007-10-29 2009-05-07 Lupin Limited Controlled release pharmaceutical compositions of tolterodine
US20090192228A1 (en) 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090247628A1 (en) 2008-03-25 2009-10-01 Auspex Pharmaceuticals, Inc. Substituted phenylcyclohexylglycolates
CA2774992A1 (en) * 2009-10-07 2011-04-14 Merck Sharp & Dohme Corp. Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
AU2011235863A1 (en) 2010-04-01 2012-11-01 Theravida, Inc. Methods of improving quality of sleep
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
AU2012253667B2 (en) 2011-05-10 2017-06-01 Theravida, Inc. Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
US20120289560A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
US20140037713A1 (en) 2012-08-03 2014-02-06 Antares Pharma Ipl, Ag Transdermal compositions for anti-cholinergic agents
WO2014059309A1 (en) 2012-10-11 2014-04-17 Theravida, Inc. Pharmaceutical formulations of pilocarpine

Also Published As

Publication number Publication date
US20120289544A1 (en) 2012-11-15
JP2014516952A (ja) 2014-07-17
NZ617375A (en) 2016-04-29
ZA201309334B (en) 2014-08-27
RU2013149635A (ru) 2015-06-20
SG194809A1 (en) 2013-12-30
AU2012253667A1 (en) 2013-11-21
KR20140044816A (ko) 2014-04-15
US9744157B2 (en) 2017-08-29
RU2671575C2 (ru) 2018-11-02
EP3167885A1 (en) 2017-05-17
JP6499634B2 (ja) 2019-04-10
US9132124B2 (en) 2015-09-15
IL229280A0 (en) 2014-01-30
EP2706997A1 (en) 2014-03-19
US8940763B2 (en) 2015-01-27
AU2012253667B2 (en) 2017-06-01
MX2013013125A (es) 2014-02-27
JP6068447B2 (ja) 2017-01-25
US20120289543A1 (en) 2012-11-15
CN103813792B (zh) 2015-11-25
MX348723B (es) 2017-06-27
WO2012154774A1 (en) 2012-11-15
IL229280B (en) 2018-08-30
CA2835277A1 (en) 2012-11-15
JP2017078089A (ja) 2017-04-27
IL260345A (en) 2018-08-30
EP2706997B1 (en) 2019-03-27
CN103813792A (zh) 2014-05-21
US20160213650A1 (en) 2016-07-28

Similar Documents

Publication Publication Date Title
BR112013028778A2 (pt) processo para laminação e estiramento de uma chapa para uma fita
ES2554796T3 (es) Dispositivo y procedimiento para la aplicación de tinta sobre una placa de vidrio
BR112017014901A2 (pt) sistema de empunhadura de paralelas retrátil para realizar execicíos de paralelas em um aparelho de exercícios
BR112013024705A2 (pt) aparelho para a produção de uma manta microtexturizada
PE20141797A1 (es) Bloque para construccion y metodo de construccion con dicho bloque
BR112015023413A2 (pt) verificação de localização de múltiplos fatores
BR112013028755A2 (pt) combinações de solifenacina e estimulantes salivares para o tratamento de bexiga hiperativa
BR112013022796A2 (pt) filme de polipropileno biaxialmente estirado, filme metalizado, e capacitor de filme
MX2017016709A (es) Capas intermedias polimericas que tienen rugosidad de superficie aumentada.
BR112015029686A2 (pt) composições para o tratamento de superfícies compreendendo corantes fotocrômicos
BR112015024488A2 (pt) dispositivo de armazenamento que tem elevações tridimensionais
BR112015022197A2 (pt) tratamento de cataplexia
BR112014005006A2 (pt) método implementado por computador
BR112016010454A2 (pt) métodos para tratar uma taupatia
MX2017003743A (es) Pelicula intercapa para vidrio laminado, y vidrio laminado.
MX2015009120A (es) Peliculas sopladas en multicapas mejoradas.
MX2017016278A (es) Pila optica que incluye polarizador reflector absorbente.
BR112015021242A2 (pt) filme com segmentos em camadas e aparelho e método para a produção do mesmo
BR112016028225A2 (pt) processo para produção de laminados flexíveis orgânico-inorgânicos
BR112014017114A8 (pt) processo para produzir um painel de vidro laminado, dispositivo para tratar a laser um filme de polímero revestido, e, uso de um dispositivo
CR20150211A (es) Compuestos diméricos
BR112015021590A2 (pt) aparelho para trocar os rolos de uma máquina de endireitamento e conjunto que comprende uma máquina de endireitamento e um aparelho
BR112014007446A2 (pt) ferramenta de segmentação
BR112015008824A2 (pt) linhagens melhoradas de microalgas e processo das mesmas
CO2022014673A2 (es) Nuevos compuestos útiles para el tratamiento y/o prevención de una enfermedad, trastorno o afección asociada con la angiotensina ii

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B12F Other appeals [chapter 12.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements